Administrative Core

行政核心

• 批准号: 9752961
• 负责人: Haifa Shen
• 金额: $ 63.37万
• 依托单位: METHODIST HOSPITAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9752961
• 关键词: Administrator; Advisory Committees; Biological; Budgets; Cancer Biology; Cancer Center; Cancer Immunology Science; Cancer Model; Cells; Clinical Cancer Center; Communication; Communities; Consultations; Data; Dendritic Cell Vaccine; Dendritic Cells; Direct Costs; Education and Outreach; Ensure; Evaluation; Faculty; Funding; Future; Goals; Immune; Immune response; Immunotherapeutic agent; Infrastructure; Institution; Intellectual Property; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical center; Methodist Church; Modeling; National Cancer Institute; Nutrient; Pancreatic Ductal Adenocarcinoma; Patients; Performance; Pharmaceutical Preparations; Pilot Projects; Principal Investigator; Property; Research; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Resources; Scientist; Students; Teacher Professional Development; Technology; Technology Transfer; Texas; Training and Education; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Vaccination; Wages; Work; breast cancer vaccine; cancer immunotherapy; clinical translation; conflict resolution; data management; design; effector T cell; imaging capabilities; immunogenic; immunogenicity; improved; malignant breast neoplasm; meetings; member; oncology; physical property; physical science; programs; recruit; tumor microenvironment; tumor progression

ADMINISTRATIVE CORE – SUMMARY The proposed Center for Immunotherapeutic Transport Oncophysics (CITO) is focused on identifying and understanding the multi-scale transport properties of immune cells and molecules, both systemically and within the tumor microenvironment, and other specific biological and physical properties of the tumor microenvironment, to ultimately develop effective cancer immunotherapies. The major CITO components are summarized as follows. Project 1 proposes to determine the transport phenomena of dendritic cell (DC) vaccines for breast and pancreatic cancers and post-vaccination changes in the transport of endogenous DCs, effector T cells, and macromolecular drugs. This information will be used to improve immune responses in these two cancer models. Project 2 seeks to determine the effects of multi-scale transport phenomena of pancreatic ductal adenocarcinoma (PDAC) on the distribution of immune cells and nutrients in the tumor microenvironment, during tumor progression. The Transport Oncophysics Core (TOC) will support both projects with modeling, computational, and imaging capabilities to integrate the scientific data into parameters that ultimately inform the rational design of optimal cancer immunotherapeutics and to improve the immunogenicity of breast and pancreatic cancers, both of which are historically known to be lowly immunogenic. The Education and Outreach Unit (EOU) will serve as the communication and engagement platform for students, trainees, junior faculty investigators, and researchers of the CITO, and those of the Physical Sciences-Oncology Network (PS-ON) and beyond. The Administrative Core (AC) will be established as part of the CITO infrastructure through which the Principal Investigator (PI), Project Co-Leaders and Core Leader, researchers, trainees, advisors, NCI PS-ON program staff, and other scientific and patient communities can share information and synergize CITO-related activities. The AC will facilitate the accomplishment and evaluation of progress and the creation of a collaborative network for current and future scientists in physical sciences oncology. The AC will also oversee and manage the selection and funding of Pilot and Trans-Network Projects, coordinate the use of shared resources and facilities, and promote interaction with other PS-ON investigators. Dr. Mauro Ferrari (Center PI, senior physical sciences investigator, AC Co-Leader, TOC Leader; Houston Methodist Research Institute, HMRI) will serve as the AC Co-Leader (10% effort). Dr. Elizabeth Mittendorf (Center cancer clinical translation investigator; AC Co-Leader; Project 1 Co-Leader; MD Anderson Cancer Center), Dr. Rongfu Wang (Center senior cancer immunology investigator; AC Co-Leader; Project 1 Co-Leader; HMRI), and Dr. Rolf Brekken (senior cancer biology investigator; AC Co- Leader; Project 2 Co-Leader; UT Southwestern Medical Center) will also serve as the other three AC Co- Leaders (5% effort each in the AC). They will be supported by a Center Administrator and staff.

行政核心——总结 拟议的免疫治疗运输肿瘤物理学中心 (CITO) 的重点是识别和 了解免疫细胞和分子的多尺度运输特性，包括系统性和 肿瘤微环境内，以及肿瘤的其他特定生物学和物理特性 微环境，最终开发有效的癌症免疫疗法 CITO 的主要组成部分。 项目1提出确定树突状细胞（DC）的运输现象。 乳腺癌和胰腺癌疫苗以及疫苗接种后内源性 DC 运输的变化， 该信息将用于改善免疫反应。 项目 2 旨在确定这两种癌症模型的多尺度传输现象的影响。 胰腺导管腺癌（PDAC）对肿瘤中免疫细胞和营养物质分布的影响 肿瘤进展过程中的微环境，运输肿瘤物理学核心 (TOC) 将支持两者。 具有建模、计算和成像功能的项目，可将科学数据集成到参数中 最终为癌症免疫疗法的合理设计提供最佳信息，并改善 乳腺癌和胰腺癌的免疫原性，历史上已知这两种癌症的免疫原性都很低 教育和外展部门（EOU）将充当沟通和参与的角色。 为 CITO 和 CITO 的学生、实习生、初级教师调查员和研究人员提供的平台 将建立物理科学-肿瘤学网络（PS-ON）及其他管理核心（AC）。 作为 CITO 基础设施的一部分，首席研究员 (PI)、项目联合领导者和核心人员通过该基础设施 领导者、研究人员、学员、顾问、NCI PS-ON 项目工作人员以及其他科学家和患者 社区可以共享信息并协同 CITO 相关活动。 成就和进展评估以及当前和未来协作网络的创建 AC 还将监督和管理物理科学肿瘤学科学家的选择和资助。 试点和跨网络项目，协调共享资源和设施的使用，促进 与其他 PS-ON 研究人员的互动 Mauro Ferrari 博士（中心 PI，高级物理科学研究员， AC 联合负责人、TOC 负责人；休斯顿卫理公会研究所 (HMRI) 将担任 AC 联合负责人 （10% 的努力）Elizabeth Mittendorf 博士（中心癌症临床翻译研究员；AC 联合负责人；项目 1）。 MD安德森癌症中心联合负责人，王荣福博士（中心高级癌症免疫学研究员； AC 联合负责人；项目 1 HMRI 联合负责人）和 Rolf Brekken 博士（高级癌症生物学研究员；AC 联合- 负责人；项目 2 联合负责人；UT 西南医学中心）也将担任其他三位 AC 联合负责人 领导者（AC 中各 5% 的努力） 他们将得到中心管理员和工作人员的支持。